Zealand Pharma's deficit grows in quarter with product divestment

The Danish biotech company has also lowered its full-year expectations for rescue pen Zegalogue.

Photo: Zealand Pharma / PR

Zealand Pharma has been busy during the year’s second quarter, where the biotech firm completed a directed share issuance, received data from the substance dapiglutide against obesity and sold off insulin pump V-Go.

On the top line, the company generated DKK 28.4m (USD 3.9m) during the three months of April, May, and June, which lead to a net deficit of DKK 432.4m (USD 60m), which fell short of comparable periods last year when revenue amounted to DKK 36.5m (USD 5.1m) and the deficit totaled DKK 297.4m (USD 41m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs